Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review

Title:Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review

Volume: 10 Issue: 3

Author(s): Douglas R. Abdalla, Cindy Simoens, John-Paul Bogers, Eddie F.C. Murta and Marcia A. Michelin

Affiliation:

Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.

Abstract: The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.

Cite this article as:

Abdalla R. Douglas, Simoens Cindy, Bogers John-Paul, Murta F.C. Eddie and Michelin A. Marcia, Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (3) . https://dx.doi.org/10.2174/1574892810999150827153642